Cadent (Carlstadt, New Jersey) reported that the American Board of Orthodontists will incorporate digital study models, including Cadent’s OrthoCAD, in its clinical evaluation board certification process no later than February 2009, enabling orthodontists to submit digital models for case data and final records as part of the examination process to earn the board’s certification.

Cadent’s OrthoCAD technology is designed to enable practitioners to visualize cases electronically without the need to create and store plaster models of each patient’s teeth. Orthodontists can assess case complexity on pre-treatment models and review clinical treatment results. This makes the analytic and treatment planning processes more efficient, according to Cadent. A digital file copy of all data and measurements for future reference is created, and if a second opinion is needed, the doctor can electronically collaborate with colleagues on a treatment plan.

OrthoCAD software also now contains ABO functions enabling orthodontists to assess case complexity on pre-treatment models and score the finished cases using the ABO grading system, Cadent said.

Cadent provides 3-D digital solutions for the orthodontic and dental industries.

Biomoda begins trading on OTC Bulletin

Biomoda (Albuquerque, New Mexico), a developer of early lung cancer detection testing and other cancer diagnostic technology, said its common stock has begun trading on the OTC Bulletin Board under the ticker symbol BMOD.

Biomoda’s technology is based on a porphyr application that preferentially binds to cancerous or aberrant cells that are extracted from lung sputum samples, the company said. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The technology, a non-invasive cytology based assay, is amenable to use by automated sample reading equipment platforms. According to Biomoda, this will allow large populations to be screened for cancer at a reasonable cost with high specificity and greater sensitivity and accuracy than most other types of cancer screening.